Publications by authors named "Byung-Wan Lee"

Objectives: Observational studies have reported that diabetes is a risk factor that increases the risk of atherosclerotic cardiovascular disease (ASCVD). However, the causal relationship remains a matter of debate. This study aimed to analyze the relationship between fasting serum glucose (FSG) and ASCVD.

View Article and Find Full Text PDF
Article Synopsis
  • * The recent term MAFLD improves upon NAFLD by including metabolic dysfunction in its diagnosis, simplifying the criteria for identification.
  • * A new classification named steatotic liver disease (SLD) has emerged in 2023, which further categorizes liver diseases based on metabolic dysfunction, with the term MASLD gaining support for its clearer diagnostic approach.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess how effective and safe add-on dapagliflozin is for type 2 diabetes patients who weren't properly managing their blood sugar levels with metformin and linagliptin.
  • In a trial with 235 patients, half received a fixed-dose combination of dapagliflozin and linagliptin, while the other half received linagliptin plus a placebo, with results measured after 24 weeks.
  • The dapagliflozin group showed significantly lower HbA1c levels and better outcomes in achieving target blood sugar levels compared to the placebo group, with a low risk of adverse effects being noted for both treatments.
View Article and Find Full Text PDF

Background And Objectives: Despite the mechanistic potential of sodium-glucose cotransporter 2 inhibitor (SGLT2i) to improve neurologic outcomes, the efficacy of SGLT2i in neurodegenerative disorders among patients with type 2 diabetes is not well established. This population-based cohort study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson disease (PD) in patients with type 2 diabetes.

Methods: This was a retrospective examination of data from a cohort of 1,348,362 participants with type 2 diabetes (≥40 years), who started antidiabetic drugs from 2014 to 2019, evaluated using the Korean National Health Insurance Service Database.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to determine the efficacy and safety profile of pioglitazone compared with placebo (PBO) in patients with type 2 diabetes (T2D) inadequately controlled with metformin and dapagliflozin.

Methods: In this prospective, multicenter, randomized, double-blind, PBO-controlled trial, 366 patients with T2D who did not meet glycemic targets (7.0% ≤ glycosylated hemoglobin [HbA] ≤ 10.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effectiveness and tolerability of combining irbesartan (IRB) and amlodipine (AML) in treating essential hypertension when IRB alone was insufficient.
  • Two phase III clinical trials in Korea involved 428 patients and compared combinations of IRB/AML to placebo over 8 weeks, focusing on changes in mean sitting systolic blood pressure (MSSBP).
  • Results showed significant reductions in MSSBP in the combination groups compared to monotherapy, with adverse events occurring in a small percentage of participants, indicating the combined therapy was both effective and tolerable.
View Article and Find Full Text PDF

Aim: To evaluate the long-term safety and efficacy of enavogliflozin 0.3 mg/day added to metformin in patients with type 2 diabetes mellitus.

Materials And Methods: After 24 weeks of a randomized, double-blind treatment period with enavogliflozin 0.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the safety and effectiveness of dulaglutide in Korean adults with type 2 diabetes over a six-year period across 85 healthcare centers.
  • Data from 3,067 subjects showed that while there were 819 reported adverse events (68 serious), dulaglutide was mostly well tolerated, and only one death occurred.
  • At 12 and 24 weeks, significant improvements in blood sugar levels (HbA1c and fasting plasma glucose) and body weight were found, indicating that dulaglutide is an effective treatment option for this demographic.
View Article and Find Full Text PDF

Aim: Hepatic ketogenesis is a key metabolic pathway that regulates energy homeostasis. Some related controversies exist regarding the pathogenesis of metabolic-associated fatty liver disease (MAFLD). We aimed to investigate whether intact ketogenic capacity could reduce the risk of MAFLD based on transient electrography (TE) in patients with newly diagnosed type 2 diabetes (T2D).

View Article and Find Full Text PDF

Background And Aims: The incidence of statin-induced new-onset diabetes (NOD) is increasing but its underlying mechanisms remain unclear. We aimed to investigate the effects of various doses of atorvastatin (ATO)-induced autophagy on the development of NOD.

Methods And Results: The isolated rat islets and MIN6 cells-treated with ATO, exhibited impaired glucose-stimulated insulin secretion, reduced insulin content, and induced apoptosis.

View Article and Find Full Text PDF

Introduction: Glucagon-like peptide-1 receptor agonists are well-established type 2 diabetes (T2D) treatments. As variations among populations and culture might influence treatment effects, this post hoc analysis evaluates the efficacy and safety of once-weekly (OW) semaglutide in a Korean population.

Methods: Korean adults with T2D inadequately controlled on metformin included in a 30-week, phase 3a, international, multicentre trial (NCT03061214) compared OW subcutaneous semaglutide (0.

View Article and Find Full Text PDF

Background: A new fatty liver disease nomenclature, steatotic liver disease (SLD) has been proposed; however, there are no data on clinical outcomes. We investigated the impact of SLD with metabolic dysfunction (MD; SLD-MD) on all-cause mortality.

Methods: We evaluated nationally representative participants aged ≥19 years using data from the Korea National Health and Nutrition Examination Survey 2007-2015 and their linked death data through 2019.

View Article and Find Full Text PDF

Background/aims: : Reports on the association between sarcopenic visceral obesity and non-alcoholic fatty liver disease (NAFLD)-associated morbidities remain scarce. We investigated the association between sarcopenia and visceral obesity, and the influence of this association on hepatic and coronary comorbidities.

Methods: : The appendicular skeletal muscle mass to visceral fat area ratio (SV ratio) was evaluated using bioelectric impedance analysis.

View Article and Find Full Text PDF

Metabolic (dysfunction) associated fatty liver disease (MAFLD) is generally developed with excessive accumulation of lipids in the liver. Ketogenesis is an efficient pathway for the disposal of fatty acids in the liver and its metabolic benefits have been reported. In this review, we examined previous studies on the association between ketogenesis and MAFLD and reviewed the candidate mechanisms that can explain this association.

View Article and Find Full Text PDF
Article Synopsis
  • In the FIDELIO-DKD study, finerenone was shown to significantly improve heart and kidney health in patients with chronic kidney disease and type 2 diabetes, especially in the Asian population.
  • A post hoc analysis of 1,327 Asian patients found that finerenone reduced risks of kidney failure and cardiovascular issues compared to a placebo.
  • The benefits and safety of finerenone were consistent across both Asian and non-Asian patients, suggesting its effectiveness is universal.
View Article and Find Full Text PDF

Aims: To compare the effectiveness and safety of empagliflozin and dulaglutide in patients with type 2 diabetes (T2D) inadequately controlled by oral triple therapy.

Methods: In this 24-week, multi-center, randomized trial, patients with T2D and HbA level ≥7.5% (58 mmol/mol) on metformin, sulfonylurea, and dipeptidyl peptidase 4 inhibitor (DPP4-i) were randomly assigned into two groups: daily empagliflozin add-on or once-weekly dulaglutide switched from DPP4-i.

View Article and Find Full Text PDF

Metabolic-associated fatty liver disease (MAFLD) and diabetic kidney disease (DKD) share various pathophysiological factors, and epidemiological evidence suggests that these two diseases are associated. Albuminuria and the estimated glomerular filtration rate, which are conventional biomarkers of DKD, are reportedly associated with the risk or severity of MAFLD. Recently, novel DKD biomarkers reflecting renal tubular injury have been introduced to complement conventional DKD markers.

View Article and Find Full Text PDF

Introduction: To investigate the safety and effectiveness of insulin degludec (IDeg) in a real-world population of Korean patients with diabetes requiring insulin therapy.

Methods: This was a multicenter, prospective, single-arm, open-label, non-interventional study. Patients aged ≥ 12 months and treated with previous glucose-lowering medications were eligible to switch to IDeg.

View Article and Find Full Text PDF

Backgruound: This study evaluated the efficacy and safety of add-on gemigliptin in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with metformin and dapagliflozin.

Methods: In this randomized, placebo-controlled, parallel-group, double-blind, phase III study, 315 patients were randomized to receive either gemigliptin 50 mg (n=159) or placebo (n=156) with metformin and dapagliflozin for 24 weeks. After the 24-week treatment, patients who received the placebo were switched to gemigliptin, and all patients were treated with gemigliptin for an additional 28 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the risks of sarcopenia (muscle loss) and cardiovascular disease (CVD) in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) versus non-metabolic risk non-alcoholic fatty liver disease (NAFLD).
  • Out of 7,248 subjects with fatty liver, higher risks of both sarcopenia and ASCVD were found in the MAFLD group compared to the non-MR NAFLD group, suggesting MAFLD patients face greater health risks.
  • The findings indicate that MAFLD criteria may more effectively identify individuals at high risk for complications than the traditional NAFLD criteria.
View Article and Find Full Text PDF

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-label trial, insulin-naive adults (≥18 years of age) with type 2 diabetes (T2D) uncontrolled on metformin (with or without a sulphonylurea) were randomized 1:1:1:1 to weekly tirzepatide 5 mg, 10 mg or 15 mg or daily insulin glargine at 66 hospitals in China, South Korea, Australia and India. The primary endpoint was non-inferiority of mean change in hemoglobin A1c (HbA1c) from baseline to week 40 after treatment with 10 mg and 15 mg of tirzepatide.

View Article and Find Full Text PDF

Background: Although the clinical outcomes of diabetes have improved, diabetes remains the principal cause of end-stage renal disease. The aim of the study is to investigate whether mortality trends in individuals with type 2 diabetes and kidney transplantation (KT) have changed.

Methods: This study analyzed data from the National Health Insurance Service claims database linked to death records from the National Statistical Information Service in Korea.

View Article and Find Full Text PDF

Aims: The ketogenic pathway is an effective mechanism by which the liver disposes of fatty acids (FAs) to the peripheral tissues. Impaired ketogenesis is presumed to be related to the pathogenesis of metabolic-associated fatty liver disease (MAFLD), but the results of previous studies have been controversial. Therefore, we investigated the association between ketogenic capacity and MAFLD in subjects with type 2 diabetes (T2D).

View Article and Find Full Text PDF